SURVEY deadline extended – The use and development of ChemoCare Electronic Prescribing System for systemic anti-cancer therapy

Dear Oncology/Haematology Pharmacist,

You are invited to participate in a survey exploring the factors that influence UK-registered pharmacists’ use and the development of ChemoCare Electronic Prescribing system (EPS) for systemic anti-cancer therapy (SACT). We hope to learn which factors (such as perceived usefulness, ease of use, social influence, supporting resources, enjoyment, perceived value and habits) are most important in shaping pharmacists’ engagement with ChemoCare EPS. The findings from this study may help inform strategies for the effective implementation, adoption, and ongoing development of ChemoCare and similar EPSs.

Time required: -15-20 minutes

Consent and survey Link: https://forms.office.com/Pages/ResponsePage.aspx?id=z8oksN7eQUKhXDyX1VPp80BNOFX5nBZEigFaU-yegcBUOUNQQkhZRk84SFAwVDRRNkJVVVBRSjUwUS4u

Deadline extended: 11th July 2025

The survey has been approved by the University of Birmingham ethics committee.  It is also supported by the organisation BOPA, that has kindly agreed to distribute the survey.  This research is not funded by ChemoCare or any other organisation.

Thank you sincerely for your time and contribution!

Regards, Elida Mudaly

Latest News

By BOPA Executive Committee on 4th November 2025

Joint BOPA and PASG Position Statement Safer Handling of Hazardous SACT Drugs: A Pharmacy Workforce Position Statement

BOPA and PASG Publish Joint Position Statement on the Safer Handling of Hazardous SACT Drugs The British Oncology Pharmacy Association (BOPA) and the NHS Pharmaceutical Aseptic Services Group (PASG) have…

Read article
By Jennifer Allen - LCC Lead on 4th November 2025

BOPA’s Let’s Communicate Cancer (LCC) series receives re-accreditation from the Royal Society for Public Health (RSPH)

The Let’s Communicate Cancer (LCC) series, available for free on the BOPA website CancerHUB: Home Page – BOPA, has recently received re-accreditation from the Royal Society for Public Health which…

Read article
By BOPA Executive Committee on 3rd November 2025

BOPA’s Submission for the National Cancer Plan for England 2025 – Call for Evidence

With the National Cancer Plan 2025 for England Publication imminent (Shaping the national cancer plan – GOV.UK) – please find BOPA’s Submission for the call for evidence below: BOPA Submission…

Read article
By BOPA IOSIG on 1st November 2025

IOCN UK-wide Survey: Access to Immunosuppressants for ICI Adverse Events

  IOCN UK-wide Survey: Access to Immunosuppressants for ICI Adverse Events Have your say on a critical issue affecting immunotherapy patients across the UK. The IOCN and UKSACT Board have…

Read article